This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Papanicolaou, D. A. Search for Related Content PubMed PubMed Citation Articles by Papanicolaou, D. A. Pubmed/NCBI databases Substance via MeSH

Interleukin-6: The Endocrine Cytokine

Pediatric and Reproductive Endocrinology Branch NICHD, National Institutes of Health Bethesda, Maryland 20892-1583 Alexandros N. Vgontzas, M.D. Sleep Research and Treatment Center Department of Psychiatry, College of Medicine Penn State University Hershey, Pennsylvania 17033

Address correspondence and requests for reprints to: Dimitris A. Papanicolaou, Pediatric and Reproductive Endocrinology Branch, NICHD, National Institutes of Health, Building 10, Room 9D42, 10 Center Drive, MSC 1583, Bethesda, Maryland 20892-1583. E-mail: papanicd{at}mail.nih.gov

	Introduction

Top Introduction References

 
The field of cytokines has expanded tremendously over the last 2 decades. Initially, they were thought to be products of the immune system alone that had immune and hematological functions only. Yet, it has become increasingly apparent that cytokines participate in a neuroendocrine and immune system network, in which both the nervous and endocrine systems participate. Interleukin-6 (IL-6) and, to a lesser extent, tumor necrosis factor have been shown to have endocrine as well as autocrine and paracrine roles. IL-6, in particular, has drawn much attention in the endocrine field for it is the most "endocrine" of all cytokines. The current issue hosts two articles that further expand our knowledge in the endocrine significance of IL-6.

IL-6 is a pleiotropic cytokine with many pathophysiologic roles in humans (1). It is being produced by numerous types of immune or immune accessory cells, such as monocytes, fibroblasts, lymphocytes, and glial cells. It is also produced by nonimmune cells, some typically endocrine. Recently, it has been shown that IL-6 and tumor necrosis factor- are produced by the adipose tissue (2, 3), suggesting that they may be playing significant roles in lipid metabolism. IL-6 is a hormonally regulated cytokine. Its production is suppressed by glucocorticoids (4) and estrogens (5) and stimulated by catecholamines (6, 7). In turn, it has many endocrine effects. It is one of the major cytokines that stimulate the hypothalamic-pituitary-adrenal axis during inflammatory stress (8); it promotes osteoclastogenesis and participates in the development of osteoporosis associated with estrogen withdrawal (9); it plays a central role in the pathogenesis of the euthyroid sick syndrome (10), most likely by inhibiting 5'-deiodinase that converts T₄ to T₃ and reverse T₃ to diiodothyronine (11). IL-6 was also shown to influence intermediary metabolism (12), to be secreted in a circadian fashion correlating with sleepiness, and to be stimulated by acute sleep deprivation (13).

The study by Fernandez-Real et al. (14) in this issue shows that a certain polymorphism in the promoter region of the IL-6 gene results in constitutively higher circulating IL-6 levels, as well as higher circulating triglyceride but not total cholesterol levels, suggesting that changes in the IL-6 gene expression can affect lipid levels through changes in IL-6 production. It has been suggested that IL-6 may cause an increase in circulating lipid levels probably through a decrease in peripheral lipoprotein lipase activity (15). However, the effects of IL-6 on lipid metabolism are far more complex. For example, administration of recombinant human IL-6 was followed by reduction in circulating triglyceride levels in normal volunteers (16). In the same study, total cholesterol as well as apoprotein B levels were decreased after administration of IL-6. Reduction of total cholesterol levels after administration of IL-6 has been observed in nonhuman primates (17) and cancer patients (18), as well. Furthermore, IL-6 levels correlate negatively with cholesterol levels after major surgery (19, 20), in patients undergoing hemodialysis (21), or after myocardial infarction (22). These apparently contradictory data may, indeed, reflect different processes.

In the study by Fernandez-Real et al. (14), circulating IL-6 levels correlated positively with circulating triglyceride levels in subjects otherwise normal and in no acute distress. None of these subjects was acutely ill, and the levels of circulating IL-6 were within the normal range. On the other hand, in situations of severe stress—such as major surgery, sepsis, and severe illness—much higher concentrations of circulating IL-6 have been reported that reach 10–1000 times the normal levels. During such situations, activation of the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system is invariably present, besides stimulation of IL-6 production. In addition, the acute phase response is being activated, and this includes suppression of the hepatic production of certain lipoproteins, as well. Thus, it seems that the effects of IL-6 on lipid metabolism depend on the extent of IL-6 induction. It is possible that in the basal, healthy state IL-6 may be influencing triglyceride levels by decreasing lipoprotein lipase activity, without effect on cholesterol concentration. On the other hand, in situations of severe stress, when the acute phase response is activated, along with the nervous and the endocrine systems, the effects on lipid metabolism are far more complex. The decrease in cholesterol acutely after major surgery or a myocardial infarction may actually reflect the negative effect of IL-6 on circulating lipoproteins. Further work is needed to clarify the actions of IL-6 on lipid metabolism in different states of health and disease.

The data regarding the correlation between the polymorphism and the free fatty acid (FFA) levels are interesting, but should be considered preliminary at this stage. Specifically, in the present study there is a significant overlap in FFA levels among the different genotypes (C/C, C/G, and G/G). One would expect a "gene dose effect" on the FFA levels, being expressed as a descending trend from the homozygote to the heterozygote to the normal genotype, regarding the polymorphism. Such a trend is not evident from the data. The multiple regression model may not be the most appropriate for such a small group of subjects. Future studies, including a larger number of subjects, would be needed to clarify the potential role of the described IL-6 gene polymorphism in lipid metabolism.

The second study by Straub et al. (23) demonstrates that IL-6 levels are affected by estrogen replacement therapy in postmenopausal women. This study further extends the findings of previous studies that IL-6 production is negatively affected by estrogens (5). The study by Straub et al. (23) supports the notion that the tonic production of IL-6 is inhibited by estrogen replacement in postmenopausal women. We have shown that circulating IL-6 levels correlate with body mass index (BMI) in men (24), and Straub et al. (23) confirmed this observation in postmenopausal women. The fact that the correlation between IL-6 and BMI is lost with hormonal replacement may reflect the dampening of IL-6 production in general, affecting this particular correlation as well.

This study provides a potential mechanism for the beneficial effects of estrogen replacement therapy on long-term cardiovascular mortality in women (25, 26). It has been postulated that a chronic low-grade inflammatory state is involved in the pathogenesis of atherosclerosis and coronary artery disease. Specifically, patients with unstable angina have elevated circulating IL-6 and C-reactive protein (CRP) levels (27). Elevated circulating CRP (an acute phase reactant considered a surrogate marker of IL-6 action) has also been shown to be an independent marker of morbidity and mortality in patients with unstable angina (28). Therefore, it is plausible that estrogens exert their beneficial action on long-term cardiovascular mortality—at least partially—by decreasing the chronic production of IL-6, and, hence, the acute phase reactants. Additional studies are needed to evaluate this theory of estrogen effects, focusing on measurement of CRP, as well as of fibrinogen, both of which are stimulated by IL-6.

The suggestion by Straub et al. (23) that the correlation of IL-6 with BMI is not affected by antihypertensive treatment, including treatment with ß-blockers, should be taken with caution, considering the fact that the stimulatory effects of the sympathetic nervous system on IL-6 production through the ß-adrenergic receptor has been well established (6, 7).

The results of both studies provide further insight to the results of our study published in the same issue (29). In this study, we found that IL-6 elevation in sleep apnea correlated with both obesity and sleep disturbance. From these data we suggested that IL-6 might play a role in the increased frequency of cardiovascular complications associated with obesity and sleep apnea. Interestingly, it has been shown that sleep apnea is much less prevalent in postmenopausal women receiving estrogen replacement therapy than in those who do not (30). Therefore, it is possible that the reduction in sleep apnea in the estrogen-treated group is, at least partially, through suppression of IL-6.

In conclusion, the current studies support and extend the major role that IL-6 plays in metabolism, obesity, and sleep. The strong association of IL-6 with obesity and sleep apnea (with the potential consequences on the cardiovascular system) need to be approached in multidisciplinary studies involving investigators from endocrinology, immunology, cardiology, and the field of sleep disorders. The data from the past decade are very promising and support such initiatives.

	Acknowledgments

 
We thank Dr. G. P. Chrousos for his insightful comments and suggestions.

Received January 20, 2000.

Accepted January 24, 2000.

	References

Top Introduction References

 

1. Papanicolaou DA, Wilder RL, Manolagas SC, Chrousos GP. 1998 The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med. 128:127–137.[Abstract/Free Full Text]
2. Mohamed-Ali V, Goodrick S, Rawesh A, et al. 1997 Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-, in vivo. J Clin Endocrinol Metab. 82:4196–4200.[Abstract/Free Full Text]
3. Orban Z, Remaley AT, Sampson M, Trajanoski Z, Chrousos GP. 1999 The differential effect of food intake and ß-adrenergic stimulation on adipose-derived hormones and cytokines in man. J Clin Endocrinol Metab. 84:2126–2133.[Abstract/Free Full Text]
4. Breuninger LM, Dempsey WL, Uhl J, Murasko DM. 1993 Hydrocortisone regulation of interleukin-6 protein production by a purified population of human peripheral blood monocytes. Clin Immunol Immunopathol. 69:205–214.[CrossRef][Medline]
5. Girasole G, Jilka RL, Passeri DC, et al. 1992 17 ß-Estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens. J Clin Invest. 89:883–891.
6. van Gool J, van Vugt H, Helle M, Aarden LA. 1990 The relation among stress, adrenalin, interleukin 6 and acute phase proteins in the rat. Clin Immunol Immunopathol. 57:200–210.[CrossRef][Medline]
7. Papanicolaou DA, Petrides JS, Tsigos C, et al. 1996 Exercise stimulates interleukin-6 secretion: inhibition by glucocorticoids and correlation with catecholamines. Am J Physiol. 271:E601–E605.
8. Mastorakos G, Chrousos GP, Weber JS. 1993 Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. J Clin Endocrinol Metab. 77:1690–1694.[Abstract]
9. Manolagas SC, Jilka RL. 1995 Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med. 332:305–311.[Free Full Text]
10. Torpy DJ, Taigos C, Lotsikas AJ, Defensor R, Chrousos GP, Papanicolaou DA. 1998 Acute and delayed effects of a single-dose injection of interleukin-6 on thyroid function in healthy humans. Metabolism. 47:1289–1293.[CrossRef][Medline]
11. Boelen A, Maas MA, Lowik CW, Platvoet MC, Wiersinga WM. 1996 Induced illness in interleukin-6 (IL-6) knock-out mice: a causal role of IL-6 in the development of the low 3,5,3'-triiodothyronine syndrome. Endocrinology. 137:5250–5254.[Abstract]
12. Stouthard JM, Romijn JA, van DP, et al. 1995 Endocrinologic and metabolic effects of interleukin-6 in humans. Am J Physiol. 268:E813–E819.
13. Vgontzas AN, Papanicolaou DA, Bixler EO, et al. 1999 Circadian interleukin-6 secretion and quantity and depth of sleep. J Clin Endocrinol Metab. 84:2603–2607.[Abstract/Free Full Text]
14. Fernandez-Real JM, Broch M, Vendrell J, Rieart W. 2000 Interleukin-6 gene polymorphism and lipid abnormalities in healthy subjects. J Clin Endocrinol Metab. 85:1334–1339.[Abstract/Free Full Text]
15. Greenberg AS, Nordan RP, McIntosh J, Calvo JC, Scow RO, Jablons D. 1992 Interleukin 6 reduces lipoprotein lipase activity in adipose tissue of mice in vivo and in 3T3–L1 adipocytes: a possible role for interleukin 6 in cancer cachexia. Cancer Res. 52:4113–4116.[Abstract/Free Full Text]
16. Papanicolaou DA, Tsigos C, Torpy DJ, Defensor R, Thompson B, Chrousos GP. 1996 Serial fasting lipid profile changes after a single injection of interleukin-6 in normal volunteers. Tenth International Congress of Endocrinology, San Francisco, CA, 1996, p 346.
17. Ettinger WHJ, Sun WH, Binkley N, Kouba E, Ershler W. 1995 Interleukin-6 causes hypocholesterolemia in middle-aged and old rhesus monkeys. J Gerontol A Biol Sci Med Sci. 50:M137–M140.
18. Veldhuis GJ, Willemse PH, Sleijfer DT, et al. 1995 Toxicity and efficacy of escalating dosages of recombinant human interleukin-6 after chemotherapy in patients with breast cancer or non-small cell lung cancer. J Clin Oncol. 13:2585–2593.[Abstract]
19. Akgun S, Ertel NH, Mosenthal A, Oser W. 1998 Postsurgical reduction of serum lipoproteins: interleukin-6 and the acute-phase response. J Lab Clin Med. 131:103–108.[CrossRef][Medline]
20. Hill GE, Pohorecki R, Whitten CW. 1998 Plasma lipid concentrations correlate inversely with CPB-induced interleukin-6 release. Can J Anaesth. 45:509–514.[Medline]
21. Bologa RM, Levine DM, Parker TS, et al. 1998 Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis. 32:107–114.[Medline]
22. Brugada R, Wenger NK, Jacobson TA, Clark WS, Cotsonis G, Iglesias A. 1996 Changes in plasma cholesterol levels after hospitalization for acute coronary events. Cardiology. 87:194–199.[Medline]
23. Straub RH, Hense HW, Andus T, Scholmerich J, Riegger GAJ, Shunkert H. 2000 Hormone replacement therapy and interrelation between serum interleukin-6 and body mass index in postmenopausal women: a population study. J Clin Endocrinol Metab. 85:1340–1344.[Abstract/Free Full Text]
24. Vgontzas AN, Papanicolaou DA, Bixler EO, Kales A, Tyson K, Chrousos GP. 1997 Elevation of cytokines in disorders of excessive daytime sleepiness: role of sleep disturbance and obesity. J Clin Endocrinol Metab. 82:1313–1316.[Abstract/Free Full Text]
25. Grodstein F, Stampfer MJ, Colditz GA, et al. 1997 Postmenopausal hormone therapy and mortality (see comments). N Engl J Med. 336:1769–1775.[Abstract/Free Full Text]
26. Hulley S, Grady D, Bush T, et al. 1998 Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group (see comments). J Am Med Assoc. 280:605–613.[Abstract/Free Full Text]
27. Liuzzo G, Baisucci LM, Gallimore JR, et al. 1999 Enhanced inflammatory response in patients with preinfarction unstable angina. J Am Coll Cardiol. 34:1696–1703.[Abstract/Free Full Text]
28. Ferreiros ER, Boissonnet CP, Pizarro R, et al. 1999 Independent prognostic value of elevated C-reactive protein in unstable angina. Circulation. 100:1958–1963.[Abstract/Free Full Text]
29. Vgontzas AN, Papanicolaou DA, Bixler EO, et al. 2000 Sleep apnea and daytime sleepiness and fatigue: relations with visceral obesity, insulin resistance, and hypercytokinemia. J Clin Endocrinol Metab. 85:1151–1158.[Abstract/Free Full Text]
30. Bixler EO, Vgontzas AN, Lin HM, Vela-Bueno A, Kales A. 1999 The prevalence of sleep-disordered breathing:effects of gender. Thirteenth Annual Meeting of the Association of Professional Sleep Societies, Orlando, FL. Sleep. 22:S105.

This article has been cited by other articles:

				Y.-L. Chiu, H.-Y. Chen, Y.-F. Chuang, S.-P. Hsu, C.-F. Lai, M.-F. Pai, S.-Y. Yang, and Y.-S. Peng Association of uraemic pruritus with inflammation and hepatitis infection in haemodialysis patients Nephrol. Dial. Transplant., November 1, 2008; 23(11): 3685 - 3689. [Abstract] [Full Text] [PDF]

				J. Shen, D. K. Arnett, P. Perez-Martinez, L. D. Parnell, C.-Q. Lai, J. M. Peacock, J. E. Hixson, M. Y. Tsai, R. J. Straka, P. N. Hopkins, et al. The effect of IL6-174C/G polymorphism on postprandial triglyceride metabolism in the GOLDN study,boxs J. Lipid Res., August 1, 2008; 49(8): 1839 - 1845. [Abstract] [Full Text] [PDF]

				C. Kruschinski, T. Skripuletz, S. Bedoui, K. Raber, R. H. Straub, T. Hoffmann, K. Grote, R. Jacobs, M. Stephan, R. Pabst, et al. Postnatal Life Events Affect the Severity of Asthmatic Airway Inflammation in the Adult Rat J. Immunol., March 15, 2008; 180(6): 3919 - 3925. [Abstract] [Full Text] [PDF]

				H. F. Escobar-Morreale, M. Luque-Ramirez, and J. L. San Millan The Molecular-Genetic Basis of Functional Hyperandrogenism and the Polycystic Ovary Syndrome Endocr. Rev., April 1, 2005; 26(2): 251 - 282. [Abstract] [Full Text] [PDF]

				M. E. Trujillo, S. Sullivan, I. Harten, S. H. Schneider, A. S. Greenberg, and S. K. Fried Interleukin-6 Regulates Human Adipose Tissue Lipid Metabolism and Leptin Production in Vitro J. Clin. Endocrinol. Metab., November 1, 2004; 89(11): 5577 - 5582. [Abstract] [Full Text] [PDF]

				M. A. Febbraio, P. Ott, H. B. Nielsen, A. Steensberg, C. Keller, P. Krustrup, N. H. Secher, and B. K. Pedersen Hepatosplanchnic clearance of interleukin-6 in humans during exercise Am J Physiol Endocrinol Metab, August 1, 2003; 285(2): E397 - E402. [Abstract] [Full Text] [PDF]

				J. M. Fernandez-Real and W. Ricart Insulin Resistance and Chronic Cardiovascular Inflammatory Syndrome Endocr. Rev., June 1, 2003; 24(3): 278 - 301. [Abstract] [Full Text] [PDF]

				M. A Febbraio, A. Steensberg, C. Keller, R. L Starkie, H. B Nielsen, P. Krustrup, P. Ott, N. H Secher, and B. K Pedersen Glucose ingestion attenuates interleukin-6 release from contracting skeletal muscle in humans J. Physiol., June 1, 2003; 549(2): 607 - 612. [Abstract] [Full Text] [PDF]

				A. J. H. H. M. van Oostrom, T. P. Sijmonsma, C. Verseyden, E. H. J. M. Jansen, E. J. P. de Koning, T. J. Rabelink, and M. Castro Cabezas Postprandial recruitment of neutrophils may contribute to endothelial dysfunction J. Lipid Res., March 1, 2003; 44(3): 576 - 583. [Abstract] [Full Text] [PDF]

				M. Friedberg, E. Zoumakis, N. Hiroi, T. Bader, G. P. Chrousos, and Z.'e. Hochberg Modulation of 11{beta}-Hydroxysteroid Dehydrogenase Type 1 in Mature Human Subcutaneous Adipocytes by Hypothalamic Messengers J. Clin. Endocrinol. Metab., January 1, 2003; 88(1): 385 - 393. [Abstract] [Full Text] [PDF]

				E. A. Bermudez, N. Rifai, J. Buring, J. E. Manson, and P. M. Ridker Interrelationships Among Circulating Interleukin-6, C-Reactive Protein, and Traditional Cardiovascular Risk Factors in Women Arterioscler. Thromb. Vasc. Biol., October 1, 2002; 22(10): 1668 - 1673. [Abstract] [Full Text] [PDF]

				H.J. Lachmann, J.A. Gilbertson, J.D. Gillmore, P.N. Hawkins, and M.B. Pepys Unicentric Castleman's disease complicated by systemic AA amyloidosis: a curable disease QJM, April 1, 2002; 95(4): 211 - 218. [Abstract] [Full Text] [PDF]

				G. Villuendas, J. L. San Millan, J. Sancho, and H. F. Escobar-Morreale The -597 G->A and -174 G->C Polymorphisms in the Promoter of the IL-6 Gene Are Associated with Hyperandrogenism J. Clin. Endocrinol. Metab., March 1, 2002; 87(3): 1134 - 1141. [Abstract] [Full Text] [PDF]

				J.-M. Fernandez-Real, M. Vayreda, C. Richart, C. Gutierrez, M. Broch, J. Vendrell, and W. Ricart Circulating Interleukin 6 Levels, Blood Pressure, and Insulin Sensitivity in Apparently Healthy Men and Women J. Clin. Endocrinol. Metab., March 1, 2001; 86(3): 1154 - 1159. [Abstract] [Full Text]

This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Papanicolaou, D. A. Search for Related Content PubMed PubMed Citation Articles by Papanicolaou, D. A. Pubmed/NCBI databases Substance via MeSH